Finoriq research workspace
Black Diamond Therapeutics, Inc. (BDTX) SEC Filings & Filing Highlights
Review SEC filings, SEC-derived company events, filing highlights, source excerpts, and material disclosure activity for Black Diamond Therapeutics, Inc. (BDTX).
Company Snapshot
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Company
- Black Diamond Therapeutics, Inc. (BDTX)
- Ticker
- BDTX
- Market Cap
- $105.7M
- Latest Price
- $1.845
- Industry
- Biotech & Pharma
Black Diamond Therapeutics, Inc. (BDTX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Black Diamond Therapeutics, Inc. (BDTX).
| Event | Form | Date |
|---|---|---|
| The voting results reported below are finalOn June 26, 2026, Black Diamond Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) in a... | 8-K5.07 | 2026-06-29 |
| Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSC...Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | 8-K8.01 | 2026-05-21 |
| Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSC...Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | 8-K7.01 | 2026-05-21 |
| Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate...Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 8-K2.02 | 2026-05-07 |
| Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Prov...Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 8-K2.02 | 2026-03-16 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.